Ibn Sina Journal of Medical Science, Health & Pharmacy

Abstract

brucellosis is a serious infectious disease that can be difficult to diagnose and treat since cases can progress from acute to chronic phases. The course of the disease is significantly influenced by immunological factors, and transforming growth factor-β (TGF-β) is thought to be involved in immune response regulation, immune evasion, and chronic inflammation. With an emphasis on comparing acute and chronic instances, the current study sought to assess TGF-β levels in Jordanian brucellosis patients and investigate its potential as a biomarker for immune evasion and illness duration. Blood samples were taken from three groups as part of the study's cross-sectional, comparative design, 30 patients with acute brucellosis, 30 patients with chronic brucellosis, and 30 healthy control subjects. ELISA was used to measure TGF-β levels in addition to serological testing and clinical evaluation. The association between TGF-β levels and the severity and duration of the condition was investigated, and statistical analyses were conducted to compare results between groups. The findings demonstrated a statistically significant positive association between TGF-β levels and the duration of the condition, with chronic patients having much greater levels than acute and healthy controls. These results confirm TGF-β's function as a trustworthy biomarker for determining the phases of a disease and forecasting its progression by indicating that high levels of the protein boost the immune response and contribute to chronic inflammation. The study concludes by pointing out that TGF-β level measurement may be a useful tool for assessing and directing treatment as well as for improving knowledge of Brucella immune evasion mechanisms. This creates chances for additional applied research and investigates the possibility of using this marker in clinical settings for early intervention and illness monitoring. To support the clinical use of this marker and create focused treatment plans, more study is advised.

Keywords: TGF-Β; Brucella; Immunity and Immune Evasion;
Chronic Inflammation; Biomarkers

References

[1]   Mohammadnia-Afrouzi, M., et al. (2018). Assessment of TGF-β and IL-10 levels in human brucellosis. Central European Journal of Immunology, 43(2), 167–170. https://doi.org/10.5114/ceji.2018.79892
[2]   Sofian, M., et al. (2016). Interleukin-17 and TGF-β levels in patients with acute brucellosis. Turkish Journal of Medical Sciences, 46(5), 1361–1367. https://doi.org/10.3906/sag-1510-94
[3]   Lin, Z. Q., et al. (2020). IL-6 and INF-γ levels in patients with brucellosis in severe and mild cases. International Journal of Infectious Diseases, 98, 127–133. https://doi.org/10.1016/j.ijid.2020.06.017
[4]   Mohammadnia-Afrouzi, M., et al. (2018). Assessment of TGF-β and IL-10 levels in human brucellosis. Central European Journal of Immunology, 43(2), 167–170. https://doi.org/10.5114/ceji.2018.79892
[5]   Zafari, P., et al. (2020). A comprehensive systematic review and meta-analysis of the association between the risk of brucellosis and its focal complication and all cytokines examined in case-control studies. Journal of Infection and Public Health, 13(9), 1442–1450. https://doi.org/10.1016/j.jiph.2019.06.010
[6]   Lu, P., et al. (2025). Progress in brucellosis immune regulation inflammatory cytokine research. Journal of Infection and Public Health, 18(1), 1–8. https://doi.org/10.1016/j.jiph.2024.11.004
[7]   Yang, Y., et al. (2023). Unravelling potential biomarkers for acute and chronic brucellosis using advanced proteomic and bioinformatic methods. Journal of Infection and Public Health, 16(3), 1–8. https://doi.org/10.1016/j.jiph.2022.11.002
[8]   Mohammadnia-Afrouzi, M., et al. (2018). Assessment of TGF-β and IL-10 levels in human brucellosis. Central European Journal of Immunology, 43(2), 167–170. https://doi.org/10.5114/ceji.2018.79892
[9]   Sofian, M., et al. (2016). Interleukin-17 and TGF-β levels in patients with acute brucellosis. Turkish Journal of Medical Sciences, 46(5), 1361–1367. https://doi.org/10.3906/sag-1510-94
[10]   Shokri, M., et al. (2021). Post-treatment downregulation of type III interferons in brucellosis patients. medRxiv. https://doi.org/10.1101/2021.04.17.21255534
[11]   Lin, Z. Q., et al. (2020). IL-6 and INF-γ levels in patients with brucellosis in severe and mild cases. International Journal of Infectious Diseases, 98, 127–133. https://doi.org/10.1016/j.ijid.2020.06.017
[12]   Zafari, P., et al. (2020). A comprehensive systematic review and meta-analysis of the association between the risk of brucellosis and its focal complication and all cytokines examined in case-control studies. Journal of Infection and Public Health, 13(9), 1442–1450. https://doi.org/10.1016/j.jiph.2019.06.010
[13]   Mohammadnia-Afrouzi, M., et al. (2018). Assessment of TGF-β and IL-10 levels in human brucellosis. Central European Journal of Immunology, 43(2), 167–170. https://doi.org/10.5114/ceji.2018.79892
[14]   Sofian, M., et al. (2016). Interleukin-17 and TGF-β levels in patients with acute brucellosis. Turkish Journal of Medical Sciences, 46(5), 1361–1367. https://doi.org/10.3906/sag-1510-94
[15]   Shokri, M., et al. (2021). Post-treatment downregulationn of type III interferons in brucellosis patients. medRxiv. https://doi.org/10.1101/2021.04.17.21255534
[16]   Lin, Z. Q., et al. (2020). IL-6 and INF-γ levels in patients with brucellosis in severe and mild cases. International Journal of Infectious Diseases, 98, 127–133. https://doi.org/10.1016/j.ijid.2020.06.017
[17]   Zafari, P., et al. (2020). A comprehensive systematic review and meta-analysis of the association between the risk of brucellosis and its focal complication and all cytokines examined in case-control studies. Journal of Infection and Public Health, 13(9), 1442–1450. https://doi.org/10.1016/j.jiph.2019.06.010
[18]   Mohammadnia-Afrouzi, M., et al. (2018). Assessment of TGF-β and IL-10 levels in human brucellosis. Central European Journal of Immunology, 43(2), 167–170. https://doi.org/10.5114/ceji.2018.79892

Article history_en

Received : Oct 10, 2024

Revised : Oct 13, 2024

Accepted : Nov 10, 2024

Authors Affiliations_en

DALIA HUSSIEN NAWAFLEH

Ethics declarations_en

Acknowledgment	None
Author Contribution	All authors contributed equally to the main contributor to this paper. All authors read and approved the final paper.
Conflicts of Interest	“The authors declare no conflict of interest.”
Funding	“This research received no external funding”